Works by Yonesaka, Kimio

Results: 30

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.

Published in:

2017

By:

Naoki Takegawa;
Kimio Yonesaka;
Takegawa, Naoki;
Yonesaka, Kimio

Publication type:

journal article

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Published in:

2020

By:

Koji Haratani;
Kimio Yonesaka;
Shiki Takamura;
Osamu Maenishi;
Ryoji Kato;
Naoki Takegawa;
Hisato Kawakami;
Kaoru Tanaka;
Hidetoshi Hayashi;
Masayuki Takeda;
Naoyuki Maeda;
Takashi Kagari;
Kenji Hirotani;
Junji Tsurutani;
Kazuto Nishio;
Katsumi Doi;
Masaaki Miyazawa;
Kazuhiko Nakagawa;
Haratani, Koji;
Yonesaka, Kimio

Publication type:

journal article

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.

Published in:

Clinical Lung Cancer, 2023, v. 24, n. 6, p. 519, doi. 10.1016/j.cllc.2023.05.008

By:

Kimio Yonesaka;
Hidetoshi Hayashi;
Atsushi Nakamura;
Yuki Sato;
Koichi Azuma;
Shinya Sakata;
Motoko Tachihara;
Satoshi Ikeda;
Toshihide Yokoyama;
Kentaro Ito;
Yukihiro Yano;
Hirotaka Matsumoto;
Haruko Daga;
Akito Hata;
Kazuko Sakai;
Yasutaka Chiba;
Kazuto Nishio;
Nobuyuki Yamamoto;
Kazuhiko Nakagawal

Publication type:

Article

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.

Published in:

Cancers, 2021, v. 13, n. 5, p. 1047, doi. 10.3390/cancers13051047

By:

Yonesaka, Kimio;
Sunaga, Noriaki

Publication type:

Article

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.

Published in:

2021

By:

Kato, Ryoji;
Haratani, Koji;
Hayashi, Hidetoshi;
Sakai, Kazuko;
Sakai, Hitomi;
Kawakami, Hisato;
Tanaka, Kaoru;
Takeda, Masayuki;
Yonesaka, Kimio;
Nishio, Kazuto;
Nakagawa, Kazuhiko

Publication type:

journal article

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 599, doi. 10.1007/s10637-012-9833-7

By:

Hasegawa, Yoshikazu;
Okamoto, Isamu;
Takezawa, Ken;
Miyazaki, Masaaki;
Tsurutani, Junji;
Yonesaka, Kimio;
Morinaga, Ryotaroh;
Tsuya, Asuka;
Terashima, Masaaki;
Kudoh, Toshihiro;
Azuma, Koichi;
Kurata, Takayasu;
Nishikawa, Tatsuyuki;
Fukuoka, Masahiro;
Nishimura, Yasumasa;
Nakagawa, Kazuhiko

Publication type:

Article

Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells.

Published in:

Oncology Reports, 2019, v. 41, n. 2, p. 1059

By:

Yonesaka, Kimio;
Kobayashi, Yoshihisa;
Hayashi, Hidetoshi;
Chiba, Yasutaka;
Mitsudomi, Tetsuya;
Nakagawa, Kazuhiko

Publication type:

Article

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib.

Published in:

International Journal of Clinical Oncology, 2021, v. 26, n. 9, p. 1628, doi. 10.1007/s10147-021-01947-3

By:

Kato, Ryoji;
Hayashi, Hidetoshi;
Sakai, Kazuko;
Suzuki, Shinichiro;
Haratani, Koji;
Takahama, Takayuki;
Tanizaki, Junko;
Nonagase, Yoshikane;
Tanaka, Kaoru;
Yoshida, Takeshi;
Takeda, Masayuki;
Yonesaka, Kimio;
Kaneda, Hiroyasu;
Nishio, Kazuto;
Nakagawa, Kazuhiko

Publication type:

Article

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Published in:

International Journal of Clinical Oncology, 2011, v. 16, n. 3, p. 244, doi. 10.1007/s10147-010-0170-6

By:

Kidera, Yasuhiro;
Satoh, Taroh;
Ueda, Shinya;
Okamoto, Wataru;
Okamoto, Isamu;
Fumita, Soichi;
Yonesaka, Kimio;
Hayashi, Hidetoshi;
Makimura, Chihiro;
Okamoto, Kunio;
Kiyota, Hidemi;
Tsurutani, Junji;
Miyazaki, Masaki;
Yoshinaga, Masahiro;
Fujiwara, Kimiko;
Yamazoe, Yuzuru;
Moriyama, Kenzo;
Tsubaki, Masanobu;
Chiba, Yasutaka;
Nishida, Shozo

Publication type:

Article

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

Published in:

International Journal of Cancer, 2006, v. 118, n. 4, p. 812, doi. 10.1002/ijc.21350

By:

Yonesaka, Kimio;
Tamura, Kenji;
Kurata, Takayasu;
Satoh, Taroh;
Ikeda, Masato;
Fukuoka, Masahiro;
Nakagawa, Kazuhiko

Publication type:

Article

Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing.

Published in:

Thoracic Cancer, 2025, v. 16, n. 3, p. 1, doi. 10.1111/1759-7714.70007

By:

Shiraishi, Naoki;
Takahama, Takayuki;
Sakai, Kazuko;
Tanaka, Kaoru;
Nakagawa, Yuzuki;
Kanemura, Hiroaki;
Nakayama, Tomohiro;
Kawanaka, Yusuke;
Kurosaki, Takashi;
Suzuki, Shinichiro;
Iwasa, Tsutomu;
Tanizaki, Junko;
Inagaki, Chiaki;
Yonesaka, Kimio;
Fukuoka, Kazuya;
Mitsudomi, Tetsuya;
Nishio, Kazuto;
Hayashi, Hidetoshi;
Nakagawa, Kazuhiko

Publication type:

Article

Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report.

Published in:

Thoracic Cancer, 2023, v. 14, n. 2, p. 214, doi. 10.1111/1759-7714.14768

By:

Fujimoto, Kana;
Watanabe, Satomi;
Yasuda, Yuto;
Date, Emi;
Kawabata, Yasuhiro;
Kanemura, Hiroaki;
Takahama, Takayuki;
Yonesaka, Kimio;
Iizuka, Norishige;
Takahashi, Ken‐ichi;
Kawakami, Osamu;
Ozaki, Tomohiro;
Nakagawa, Kazuhiko

Publication type:

Article

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer.

Published in:

Thoracic Cancer, 2019, v. 10, n. 10, p. 1928, doi. 10.1111/1759-7714.13166

By:

Nonagase, Yoshikane;
Takeda, Masayuki;
Azuma, Koichi;
Hayashi, Hidetoshi;
Haratani, Koji;
Tanaka, Kaoru;
Yonesaka, Kimio;
Ishii, Hidenobu;
Hoshino, Tomoaki;
Nakagawa, Kazuhiko

Publication type:

Article

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab.

Published in:

Science Translational Medicine, 2011, v. 3, n. 99, p. 1, doi. 10.1126/scitranslmed.3002442

By:

Yonesaka, Kimio;
Zejnullahu, Kreshnik;
Okamoto, Isamu;
Satoh, Taroh;
Cappuzzo, Federico;
Souglakos, John;
Ercan, Dalia;
Rogers, Andrew;
Roncalli, Massimo;
Takeda, Masayuki;
Fujisaka, Yasuhito;
Philips, Juliet;
Shimizu, Toshio;
Maenishi, Osamu;
Yonggon Cho;
Sun, Jason;
Destro, Annarita;
Taira, Koichi;
Takeda, Koji;
Okabe, Takafumi

Publication type:

Article

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.

Published in:

2016

By:

Takeda, Masayuki;
Yamanaka, Takeharu;
Seto, Takashi;
Hayashi, Hidetoshi;
Azuma, Koichi;
Okada, Morihito;
Sugawara, Shunichi;
Daga, Haruko;
Hirashima, Tomonori;
Yonesaka, Kimio;
Urata, Yoshiko;
Murakami, Haruyasu;
Saito, Haruhiro;
Kubo, Akihito;
Sawa, Toshiyuki;
Miyahara, Eiji;
Nogami, Naoyuki;
Nakagawa, Kazuhiko;
Nakanishi, Yoichi;
Okamoto, Isamu

Publication type:

journal article

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer.

Published in:

Cancer Science, 2019, v. 110, n. 1, p. 52, doi. 10.1111/cas.13860

By:

Watanabe, Satomi;
Hayashi, Hidetoshi;
Haratani, Koji;
Shimizu, Shigeki;
Tanizaki, Junko;
Sakai, Kazuko;
Kawakami, Hisato;
Yonesaka, Kimio;
Tsurutani, Junji;
Togashi, Yosuke;
Nishio, Kazuto;
Ito, Akihiko;
Nakagawa, Kazuhiko

Publication type:

Article

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer- WJOG 6210G.

Published in:

Cancer Science, 2016, v. 107, n. 12, p. 1843, doi. 10.1111/cas.13098

By:

Shitara, Kohei;
Yonesaka, Kimio;
Denda, Tadamichi;
Yamazaki, Kentaro;
Moriwaki, Toshikazu;
Tsuda, Masahiro;
Takano, Toshimi;
Okuda, Hiroyuki;
Nishina, Tomohiro;
Sakai, Kazuko;
Nishio, Kazuto;
Tokunaga, Shoji;
Yamanaka, Takeharu;
Boku, Narikazu;
Hyodo, Ichinosuke;
Muro, Kei

Publication type:

Article

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.

Published in:

2017

By:

Shimizu, Toshio;
Yonesaka, Kimio;
Hayashi, Hidetoshi;
Iwasa, Tsutomu;
Haratani, Koji;
Yamada, Hironori;
Ohwada, Shoichi;
Kamiyama, Emi;
Nakagawa, Kazuhiko

Publication type:

journal article

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer.

Published in:

Cancer Medicine, 2019, v. 8, n. 3, p. 1258, doi. 10.1002/cam4.1995

By:

Watanabe, Satomi;
Yonesaka, Kimio;
Tanizaki, Junko;
Nonagase, Yoshikane;
Takegawa, Naoki;
Haratani, Koji;
Kawakami, Hisato;
Hayashi, Hidetoshi;
Takeda, Masayuki;
Tsurutani, Junji;
Nakagawa, Kazuhiko

Publication type:

Article

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Published in:

Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-55939-5

By:

Yonesaka, Kimio;
Iwama, Eiji;
Hayashi, Hidetoshi;
Suzuki, Shinichiro;
Kato, Ryoji;
Watanabe, Satomi;
Takahama, Takayuki;
Tanizaki, Junko;
Tanaka, Kaoru;
Takeda, Masayuki;
Sakai, Kazuko;
Azuma, Koichi;
Chiba, Yasutaka;
Atagi, Shinji;
Nishio, Kazuto;
Okamoto, Isamu;
Nakagawa, Kazuhiko

Publication type:

Article

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.

Published in:

Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-47673-9

By:

Sakai, Kazuko;
Takeda, Masayuki;
Shimizu, Shigeki;
Takahama, Takayuki;
Yoshida, Takeshi;
Watanabe, Satomi;
Iwasa, Tsutomu;
Yonesaka, Kimio;
Suzuki, Shinichiro;
Hayashi, Hidetoshi;
Kawakami, Hisato;
Nonagase, Yoshikane;
Tanaka, Kaoru;
Tsurutani, Junji;
Saigoh, Kazumasa;
Ito, Akihiko;
Mitsudomi, Tetsuya;
Nakagawa, Kazuhiko;
Nishio, Kazuto

Publication type:

Article

Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer.

Published in:

Clinical Case Reports, 2016, v. 4, n. 5, p. 481, doi. 10.1002/ccr3.547

By:

Ota, Takayo;
Suzumura, Tomohiro;
Sugiura, Takamune;
Hasegawa, Yoshikazu;
Yonesaka, Kimio;
Makihara, Masaru;
Tsukuda, Hiroshi;
Tada, Takuhito;
Fukuoka, Masahiro

Publication type:

Article

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.

Published in:

Oncogenesis, 2019, v. 8, n. 10, p. N.PAG, doi. 10.1038/s41389-019-0164-9

By:

Yonesaka, Kimio;
Tanaka, Kaoru;
Kitano, Mutsukazu;
Kawakami, Hisato;
Hayashi, Hidetoshi;
Takeda, Masayuki;
Sakai, Kazuko;
Nishio, Kazuto;
Doi, Katsumi;
Nakagawa, Kazuhiko

Publication type:

Article

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.

Published in:

International Journal of Cancer, 2019, v. 145, n. 12, p. 3414, doi. 10.1002/ijc.32408

By:

Takegawa, Naoki;
Tsurutani, Junji;
Kawakami, Hisato;
Yonesaka, Kimio;
Kato, Ryoji;
Haratani, Koji;
Hayashi, Hidetoshi;
Takeda, Masayuki;
Nonagase, Yoshikane;
Maenishi, Osamu;
Nakagawa, Kazuhiko

Publication type:

Article

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Published in:

International Journal of Cancer, 2017, v. 141, n. 8, p. 1682, doi. 10.1002/ijc.30870

By:

Takegawa, Naoki;
Nonagase, Yoshikane;
Yonesaka, Kimio;
Sakai, Kazuko;
Maenishi, Osamu;
Ogitani, Yusuke;
Tamura, Takao;
Nishio, Kazuto;
Nakagawa, Kazuhiko;
Tsurutani, Junji

Publication type:

Article

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.

Published in:

PLoS ONE, 2015, v. 10, n. 11, p. 1, doi. 10.1371/journal.pone.0143132

By:

Yonesaka, Kimio;
Takegawa, Naoki;
Satoh, Taroh;
Ueda, Hiroto;
Yoshida, Takeshi;
Takeda, Masayuki;
Shimizu, Toshio;
Chiba, Yasutaka;
Okamoto, Isamu;
Nishio, Kazuto;
Tamura, Takao;
Nakagawa, Kazuhiko

Publication type:

Article

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors.

Published in:

Oncologist, 2021, v. 26, n. 4, p. e588, doi. 10.1002/onco.13639

By:

Takeda, Masayuki;
Takahama, Takayuki;
Sakai, Kazuko;
Shimizu, Shigeki;
Watanabe, Satomi;
Kawakami, Hisato;
Tanaka, Kaoru;
Sato, Chihiro;
Hayashi, Hidetoshi;
Nonagase, Yoshikane;
Yonesaka, Kimio;
Takegawa, Naoki;
Okuno, Tatsuya;
Yoshida, Takeshi;
Fumita, Soichi;
Suzuki, Shinichiro;
Haratani, Koji;
Saigoh, Kazumasa;
Ito, Akihiko;
Mitsudomi, Tetsuya

Publication type:

Article

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.

Published in:

Cells (2073-4409), 2025, v. 14, n. 6, p. 447, doi. 10.3390/cells14060447

By:

Yonesaka, Kimio;
Kurosaki, Takashi;
Tanizaki, Junko;
Kawakami, Hisato;
Tanaka, Kaoru;
Maenishi, Osamu;
Takamura, Shiki;
Sakai, Kazuko;
Chiba, Yasutaka;
Teramura, Takeshi;
Goto, Hiroki;
Otsuka, Eri;
Okida, Hiroaki;
Funabashi, Masanori;
Hashimoto, Yuuri;
Hirotani, Kenji;
Kamai, Yasuki;
Kagari, Takashi;
Nishio, Kazuto;
Kakimi, Kazuhiro

Publication type:

Article

Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)

Published in:

Targeted Oncology, 2020, v. 15, n. 5, p. 623, doi. 10.1007/s11523-020-00750-w

By:

Izawa, Naoki;
Shitara, Kohei;
Yonesaka, Kimio;
Yamanaka, Takeharu;
Yoshino, Takayuki;
Sunakawa, Yu;
Masuishi, Toshiki;
Denda, Tadamichi;
Yamazaki, Kentaro;
Moriwaki, Toshikazu;
Okuda, Hiroyuki;
Kondoh, Chihiro;
Nishina, Tomohiro;
Makiyama, Akitaka;
Baba, Hideo;
Yamaguchi, Hironori;
Nakamura, Masato;
Hyodo, Ichinosuke;
Muro, Kei;
Nakajima, Takako Eguchi

Publication type:

Article

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Published in:

Journal of Clinical Investigation, 2020, v. 130, n. 1, p. 374, doi. 10.1172/JCI126598

By:

Koji Haratani;
Kimio Yonesaka;
Shiki Takamura;
Osamu Maenishi;
Ryoji Kato;
Naoki Takegawa;
Hisato Kawakami;
Kaoru Tanaka;
Hidetoshi Hayashi;
Masayuki Takeda;
Naoyuki Maeda;
Takashi Kagari;
Kenji Hirotani;
Junji Tsurutani;
Kazuto Nishio;
Katsumi Doi;
Masaaki Miyazawa;
Kazuhiko Nakagawa

Publication type:

Article